No Data
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
Genscript Biotech's (HKG:1548) Nasdaq-listed subsidiary Legend Biotech reported a loss of $59.8 million, or $0.16 per share, in the first quarter, down from $112.1 million, or $0.34 per share, a year
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating for Legend Biotech Anchored by Carvykti's Growth and Market Penetration Potential
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Ginvest : Thank you for the timely info
Srav Reddy : $X4 Pharmaceuticals (XFOR.US)$ announcement was early on 29/4. But price receded. This is surprising to me.